Li Ka-shing’s CK Life Sciences targets China fast track for cancer vaccine trials
CK Life Sciences, backed by Li Ka-shing’s CK Group, plans to bring its cancer vaccine candidates into mainland China through a fast-track trial channel. The move reflects Beijing’s push to speed early-stage drug development and expand biotech innovation.